Evidence Based Hair

Season 5, Episode 4 (Switching JAK Inhibitors, Ritlecitinib in Adolescents, VTE Risk in AT/AU, Habit Replacement Therapy in TTM)

STUDIES REFERENCE IN THE EPISODE
 
SWITCHING FROM TOFACITINIB TO BARICITINIB
 
Kazmi A et al (starts at 12:33). Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.
 
 
RITLECITINIB IN ADOLESCENTS
 
Hordinsky M et al (starts at 21:31). Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023 Jul 17.
 
 
RISK OF INFECTIONS, CANCER, HEART DISEASE AND BLOOD CLOTS IN AT/AU
 
George P et al (starts at 36:08). Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.
 
 
Schneeweiss MC et al (starts at 37:36). Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol. 2021 Jul 1;157(7):805-816.
 
 
MARKERS OF VENOUS THROMBOEMBOLISM IN ALOPECIA AREATA
 
Sudnik W et al (starts at 57:40) . The role of selectins in alopecia areata. Postepy Dermatol Alergol. 2015 Feb;32(1):27-32.
 
Shakoei S et al (starts at 58:23). Coagulation status in patients with alopecia areata: a cross-sectional study. Ital J Dermatol Venerol. 2021 Oct;156(5):588-592.
 
Waśkiel-Burnat A et al (starts at 59:30). Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about? Dermatol Ther (Heidelb). 2023 Aug;13(8):1847-1855.
 
 
HABIT REPLACEMENT THERAPY FOR TRICHOTILLOMANIA
 
Moritz S et al (starts at 1:04:34). Self-Help Habit Replacement in Individuals With Body-Focused Repetitive Behaviors: A Proof-of-Concept Randomized Clinical Trial.  JAMA Dermatol. 2023 Jul 19;e232167.
 
LINK TO VIDEO on HRT DEMONSTRATION https://clinical-neuropsychology.de/habit-replacement-en/#sthash.J6iQiYRi.dpuf
 
 

Season 5, Episode 3 (Ranking of Finasteride and Minoxidil Protocols for FPHL, Follow up to New York Times Aug 2022 Article, Periorbital Edema from Oral Minoxidil, TE from Anticonvulsant Medications)

Season 5, Episode 2 (CVG secondary to Psoriasis, Hair Loss from Temporal Lifts, Oral minoxidil Lung Disease, PTSD & Autoimmunity, Laser Hair Removal & Behcet’s)

NON SCARRING ALOPECIA AFTER HYALURONIC ACID TEMPORAL LIFTING TECHNIQUES
Landau M et al (starts at 9:05). Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37:30-34
Coimbra D.D., and de Oliveira B.S (starts at 10:17). Supra-auricular lifting with fillers: new technique. J Cosmet Dermatol. 2016;8(4):328–335.
 
CUTIS VERTICES GYRATA DUE TO PSORIASIS
Garcia-Rodriquez V et al (starts at 25:19). Cutis verticis gyrata secondary to scalp psoriasis. Int J Dermatol. 2023 Jun 4.
 
ORAL MINOXIDIL ASSOCIATED HYPERSENSITIVITY PNEUMONITIS
Takekosh D et al (starts at 32:35). Minoxidil-induced lung disease, masquerading as hypersensitivity pneumonitis. Respir Med Case Rep. 2023 Apr 29;43:101861.
 
PTSD AND AUTOIMMUNE DISEASE
Hsu TW et al (starts at 43:40). Risk of autoimmune diseases after post-traumatic stress disorder: A nationwide cohort study. Eur Arch Psychiatry Clin Neurosci. 2023 Jun 15.
 
Song H et al (starts at 49:18). Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018 Jun 19;319(23):2388-2400.
 
Dai Y-X et al (starts at 51:00). Posttraumatic Stress Disorder and the Associated Risk of Autoimmune Skin Diseases: A Nationwide Population-Based Cohort Study. Psychosom Med. 2021 Apr 1;83(3):212-217.
 
PATHERGY IN PATIENTS WITH BEHCET’S DISEASE RECEIVIGING LASER HAIR REMOVAL R
Nicolau et al (starts at 53:07). Pathergy-like reaction induced by laser hair removal in a patient with Behçet disease. Reumatismo. 2023 Jul 17;75(2).
Van der Ree-Pellikaan C et al (starts at 1:01:48). Oral ulcerations after placement of orthodontic braces and skin pustules after laser hair removal: novel inducers of pathergy reactions in new-onset Behçet's disease. BMJ Case Rep. 2016 Mar 7;2016:bcr2014209208. doi: 10.1136/bcr-2014-209208.

Season 5 Episode 1 (LPP Disease Associations, LPP & Thyroid, Side Effects of HCQ, Genetic Basis of Male FFA, FFA Prevalence/Incidence)

DISEASE ASSOCIATIONS IN FRONTAL FIBROSING ALOPECIA
Conic et al. Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828. 
 
Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
 
Lim SH Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235
 
 
THE RELATIONSHIP BETWEEN LPP AND HYPOTHYROIDISM
 
Joshi TP et al. Association of lichen planopilaris with hypothyroidism: a systematic review and meta-analysis. Int J Dermatol. 2023 Jul 10.
 
 
SIDE EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH SCARRING ALOPECIA  
 
Ezemma O et al. Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review. Int J Dermatol. 2023 Apr 10. doi: 10.1111/ijd.16660. Online ahead of print
 
 
GENETICS OF MALE FRONTAL FIBROSING ALOPECIA
 
Rayinda T et al. Shared Genetic Risk Variants in Both Male and Female Frontal Fibrosing Alopecia. J Invest Dermatol. 2023 May 19;S0022-202X(23)02068-7.
 
 
 
INCIDENCE AND PREVALENCE OF FRONTAL FIBROSING ALOPECIA
 
Lavian J et al. Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. Dermatol Online J. 2021 Aug 15;27(8).
 
Trager MH et al. Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169
 
Carmona-Rodriquez M et al. Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases. Life (Basel). 2023 Jun 8;13(6):1344.

Season 4, Episode 8 (Isotretinoin for SD, Iron Therapy, Memantine for TTM, Antifungal Resistance

Season 4, Episode 8

Season 4, Episode7 (Tinea with baricitinib, ADHD and AA, Upadacitinib for AA, Baricitinib 52 week data, micro needling for MPHL)

Season 4, Episode 7 Data

Season 4, Episode 6 (Scalp Neuropathy in DMS, Scurvy, Cutaneous Pili Migrans, Quiz Case, Beethoven’s Hair)

Season4, Episode 6

Season 4, Episode 5 (Hair Loss after COIVD Vaccines, FD in DEB, New DSC ”CVG” Variants, DSC After HT, DLE to SLE Progression)

Season 4, Episode 5

Season 4, Episode 4 (COVID hair loss, TE from anti-CGRP migraine meds, tinea capitis, oral minoxidil for traction alopecia

Season 4 Episode 4
 
COVID RELATED TE
Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol.  2023 Mar 8.
M Alharbi et al. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022 Oct;11(10):6056-6060.
Tahmaz A et al. [The Evaluation of Long Coronavirus Disease Symptoms at Ninth Month from a Hospital in Türkiye]. .Mikrobiyol Bul. 2022 Oct;56(4):657-666.
Saber M et al. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023 Mar 9
Lv S et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection Clin Cosmet Investig Dermatol. 2021; 14: 385–387. Published online 2021 Apr 16. 
Willimann B, et al. Hair pain (trichodynia): frequency and relationship to hair loss and patient gender. Dermatology. 2002
 
HAIR LOSS FROM ANTI-CGRP THERAPIES
Ruiz M et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023 Feb;43(2):3331024221143538.
 
Sessa M and Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35: 215–227
 
Evers S and Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023 Jan;63(1):165-167.
 
ORAL MINOXIDIL FOR TRACTION ALOPECIA
Awad A et al. Low-dose oral minoxidil improves hair density in traction alopecia. J Am Acad Dermatol. 2023 Feb 24;S0190-9622(23)00278-5.
Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.
Kim and Craiglow. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.
 
TINEA CAPITIS WORK UP AND TREATMENT IN PEDIATRICS
Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

Season 4 Episode 3 (Spironolactone for FPHL, Oral Minoxidil for Nails, Histology of AA vs AGA, AAI, Work Productivity in AA)

Season 4, Episode 3